(Q38365267)

2 September 2017

1 reference

title

Alpha-1 blockers. A new generation of antihypertensive agents (English)

1 reference

2 September 2017

Humphreys JE

1

1 reference

2 September 2017

Waite MA

series ordinal

2

1 reference

2 September 2017

publication date

1 August 1989

1 reference

Journal of Clinical Pharmacy and Therapeutics

2 September 2017

published in

1 reference

2 September 2017

volume

14

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

263-283

1 reference

Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Presynaptic regulation of catecholamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Alpha-adrenergic receptors in human blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Pharmacology of labetalol in experimental animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Short- and long-term (six-year) hemodynamic effects of labetalol in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

The alpha 1-adrenoceptor antagonist profile of doxazosin: preclinical pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Prazosin kinetics in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Prazosin disposition in young and elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Influence of congestive heart failure on prazosin kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Effects of two antihypertensive agents on lipids, lipoproteins, and apoproteins A and B. Comparison of prazosin and atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Prazosin versus captopril as initial therapy. Effect on hypertension and lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

The addition of prazosin to standard triple therapy in the treatment of severe hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Evolution of the clinical management of hypertension. Emerging role of "specific" vasodilators as initial therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Role of sympathetic blocking agents in outflow obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Clinical relevance of some findings in neuro-anatomy and neurophysiology of the lower urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Overall safety of terazosin as an antihypertensive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Risk factors for ischaemic heart disease in British men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Blood lipids in middle-aged British men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

The effects of antihypertensive agents on serum lipids and lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

High-density lipoproteins: epidemiologic profile and risks of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Effects of alpha-adrenergic and beta-adrenergic receptor blockade on lipid metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Effects of bunazosin on electrical responses of smooth muscle cells of the guinea-pig mesenteric artery and vein to perivascular nerve stimulation and to noradrenaline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Dose-titration study of alfuzosin, a new alpha 1-adrenoceptor blocker, in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

The metabolism and kinetics of doxazosin in man, mouse, rat and dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Clinical pharmacological studies with doxazosin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

The pharmacokinetics of doxazosin in elderly normotensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Acute renal effects of doxazosin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

The antihypertensive effects of doxazosin: a clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Long-term experience with terazosin for treatment of mild to moderate hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Efficacy of terazosin as an antihypertensive agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Cumulative experience with terazosin administered in combination with diuretics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Effect of terazosin on serum lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.1989.TB00248.X

10.1111/J.1365-2710.1989.TB00248.X

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference